Upstream therapies to prevent atrial fibrillation

European Heart Journal, Supplement

Volumn 10, Issue H, 2008, Pages

  Dorian, Paul ^a   Singh, Bramah N ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Atrial fibrillation; Fish oil; N 3 polyunsaturated fatty acids; Statins; Steroids; Upstream therapy

Indexed keywords

AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; RAMIPRIL; STEROID; TRANDOLAPRIL; VALSARTAN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FAT INTAKE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 58149143486     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sun033     Document Type: Review

References (104)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S (Writing Committee Members), Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B (ACC/AHA Task Force Members), Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL (ESC Committee for Practice Guidelines). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol 2006;48:e149-e246.
2. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH EURIDIS ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-999.
3. Singh BN, Aliot E. Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity? Eur Heart J 2007;9(Suppl. G):G17-G25.
4. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54: 230-246.
5. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res 2002;54:347-360.
6. Murray KT, Mace LC, Yang Z. Non-antiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 2007;4(Suppl. 3):S88-S90.
7. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger PA, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. J Am Med Assoc 1994;271: 840-844.
8. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati C. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41: 218-223.
9. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-716.
10. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000;356:1789-1794.
11. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl JMed 2002;347:1825-1833.
12. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840.
13. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U STAF Investigators. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690- 1696.
14. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
15. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-2092.
16. Boos CJ, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-149.
17. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007;115:135-143.
18. Boos CJ, Lip GYH. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 2005;19:855-859.
19. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006;27:512-518.
20. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol 2007;18: 1222-1228.
21. Van Gelder IC. Rhythm control for atrial fibrillation: non-channel antiarrhythmic drugs are en vogue. Cardiovasc Res 2007;74:8-10.
22. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-380.
23. Pizzetti F, Turazza F, Franzosi M et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: The GISSI-3 data. Heart 2001;86:527-532.
24. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 2003;107:2926- 2931.
25. Alsheikh-Ali A, Wang P, Rand W, Konstam MA, Homoud MK, Link MS, Estes NA III, Salem DN, Al-Ahmad AM. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 2004;147:1061-1065.
26. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-557.
27. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJV, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86-92.
28. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE. Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616.
29. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999;354:1751-1756.
30. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004;44:159-164.
31. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719.
32. Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, Bata I, Mann J, Matthew J, Pogue J, Yusuf S, Dagenais G, M Lonn E on behalf of the HOPE Investigators. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention evaluation study. Am Heart J 2007;154:448-453.
33. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA for the VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403-411.
34. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Failure 1995;1:355-363.
35. Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-336.
36. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090- 2098.
37. Zaman AG, Kearney MT, Schecter C, Worthley SG, Nolan J. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004;147: 823-827.
38. Van Noord T, Crijns H, van den Berg M, Van Veldhuisen D, Van Gelder I. Pretreatment with ACE-Is improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Dis 2005;5:3-8.
39. Madrid AH, Marin IM, Cervantes CE, Morell EB, Estévez JE, Moreno G, Parajón JR, Peng J, Limón L, Nannini S, Moro C. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004;5:114-120.
40. Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith P. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007;120:85-91.
41. Anné W, Willems R, van der Merwe N, van de Werf F, Ector H, Heidbüchel H. Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 2004;90:1025-1030.
42. Richter B, Derntl M, Marx M, Lercher P, Gössinger HD. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007;153:113-119.
43. Al Chekakie MO, Akar JG, Wand F, Al Muradi H, Wu J, Santucci, Varma N, Wilber DJ. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007;18: 942-946.
44. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, DiMarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA the AFFIRM Investigators. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 2004;1:669-675.
45. Hirayama Y, Atarashi H, Kobayashi Y, Horie T, Iwasaki Y, Maruyama M, Miyauchi Y, Ohara T, Yashima M, Takano T. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J 2005;69: 671-676.
46. Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E, Rinaldi A. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006;47:46-50.
47. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, Su L, Ling Z, She Q, Luo K, Woo K, Dong J. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27:1841-1846.
48. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT; Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-1729.
49. White C, Kluger J, Lertsburapa K, Faheem O, Coleman C. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg 2007;31:817-820.
50. Coleman C, Makanji S, Kluger J, White M. Effect of angiotensinconverting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation. Ann Pharmacother 2007;41:433-437.
51. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Ysuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensinconverting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839.
52. Celik T, Iyisoy A. Angiotensin receptor blockers in the prevention of atrial fibrillation recurrence: need for a definitive trial. Letter to the Editor. Int J Cardiol 2007; Epub ahead of print.
53. Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith P. Angiotensin receptor blockers in the prevention of atrial fibrillation recurrence: need for a definitive trial. Letter to the Editor. Int J Cardiol 2007; Epub ahead of print.
54. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HAJ, Zanchetti A. Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25: 1105-1187.
55. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-3548.
56. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-1184.
57. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886- 2891.
58. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-3010.
59. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1100-1107.
60. Malouf JF, Kanagala R, Al Atawi FO, Rosales AG, Davison DE, Murali NS, Tsang TS, Chandrasekaran K, Ammash NM, Friedman PA, Somers VK. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005;46:1284- 1287.
61. Loricchio M, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, Santini M. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007;99: 1421-1424.
62. Halvorsen P, Raeder J, White PF, Almdahl SM, Nordstrand K, Saatvedt K, Veel T. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth Analg 2003; 96:1578-1583.
63. Prasongsukarn K, Abel JG, Jamieson WR, Cheung A, Russell JA, Walley KR, Lichtenstein SV. The effect of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial. J Thorac Cardiovasc Surg 2005;130:93-98.
64. Halonen J, Halonen P, Järvinen O, Taskinen P, Auvinen T, Tarkka M, Hippeläinen M, Juvonen T, Hartikainen J, Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery. JAMA 2007;297:1562-1567.
65. Yared JP, Starr NJ, Torres FK, Bashour CA, Bourdakos G, Piedmonte M, Michener JA, Davis JA, Rosenberger TE. Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. Ann Thorac Surg 2000;69:1420-1424.
66. Rubens FD, Nathan H, Labow R, Williams KS, Wozny D, Karsh J, Ruel M, Mesana T. Effect of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann Thorac Surg 2005;79:655-665.
67. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007;75:10-20.
68. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92:1379-1383.
69. Merckx KL, Tieleman RG, Folkeringa RJ, Pinto YM, Nieman FH, Cheriex EC, Crijns HJ. Use of statins is associated with reduced incidence of atrial fibrillation in patients with left ventricular hypertrophy and left atrial dilatation (Abstract ID: 3669). Heart Rhythm Society 25th Annual Scientific Sessions, 28 May 2004.
70. Dernellis J, Panaretou M. Effects of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005;150: 1064.e7-1064.e12.
71. Amit G, Katz A, Bar-On S, Gilutz H, Wagshal A, Ilia R, Henkin Y. Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker. Clin Cardiol 2006;6:249-252.
72. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, Beshai JF, Langberg JJ. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006;3:881-886.
73. Adabag AS, David B, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 2007;154:1140-1145.
74. Ramani G, Zahid M, Good CB, Macioceb A, Sonel AF. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol 2007;100:404-405.
75. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92:1343-1345.
76. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004;93: 780-782.
77. Colivicchi F, Ammirati F, Santini M. Effects of statin therapy on the recurrence of persistent atrial fibrillation in patients with essential hypertension: a propensity score-adjusted analysis. (Abstract 2004-532). Heart Rhythm 2004;1(Suppl. 1): S168.
78. Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;97: 1490-1493.
79. Garcia-Fernandez A, Marin F, Mainar L, Roldan V, Martinez JG. Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;98:1299-1300.
80. Auer J, Weber T, Berent R, Lamm G, Ng CK, Hartl P, Strasser U, Eber B. Use of HMG-coenzyme a-reductase inhibitors (statins) and risk reduction of atrial fibrillation after cardiac surgery: results of the SPPAF study, a randomised placebo-controlled trial (Abstract 2045). Eur Heart J 2004;25(Suppl):353.
81. Amar D, Zhang H, Heerdt P, Park B, Fleisher M, Thaler HT. Statin use is associated with a reduction in atrial fibrillation after non cardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128:3421-3427.
82. Marin F, Pascual DA, Roldan V. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006;97:55-60.
83. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for the reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) Study. Circulation 2006;114:1455-1461.
84. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, Carassiti M, Covino E. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006;34: 660-667.
85. Ozaydin M, Dogan A, Varol E, Kapan S, Tuzun N, Peker O, Aslan SM, Altinbas A, Ocal A, Ibrisim E. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007;107:117-121.
86. Lertsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman CI. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008; 135:405-411.
87. Virani SS, Nambi V, Razavi M, Lee VV, Elayda MA, Wilson JM, Ballantyne CM. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J 2008;155:541-546.
88. Padfield GJ, Hawkins NM, MacDonald MR. Letter by Padfield et al regarding article, 'Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study'. Circulation 2007;115:e403.
89. Shroff GR, Orlandi QG. Letter by Shroff and Orlandi regarding article, 'Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study'. Circulation 2007;115: e404.
90. Patti G, Chello M, Candura D, D'Ambrosio A, Covino E, Di Sciascio G, Pasceri V. Response to Letters Regarding Article, 'Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) Study'. Circulation 2007;115:e405.
91. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2007; Epub ahead of print.
92. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828- 835.
93. Korantzopoulos P, Kolettis TM, Goudvenos JA. The anti-inflammatory and antioxidant effects of long-chain n23 fatty acids or oil-rich fish may favorably affect atrial remodeling in atrial fibrillation. Med Hypotheses 2005;64:1245-1246.
94. Liu T, Li G. Anti-inflammatory effects of long-chain omega 3 fatty acids: potential benefits for atrial fibrillation. Med Hypotheses 2005;65:200-201.
95. Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 2006;98:50i-60i.
96. Laurent G, Moe G, Hu X, Holub B, Leong-Poi H, Trogadis J, Connelly K, Courtman D, Strauss BH, Dorian P. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc Res 2008;77:89-97.
97. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Fitzpatrick A, Siscovick DS. Fish intake and risk of incident atrial fibrillation. Circulation 2004;110:368-373.
98. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 2005;45:1723-1728.
99. Frost L, Vestergaard P. N-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005;81:50-54.
100. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006;151:857-862.
101. Connolly S, Yusuf S, Budaj A, Camm J, Chrolavicius S, Commerford PJ, Flather M, Fox KA, Hart R, Hohnloser S, Joyner C, Pfeffer M, Anand I, Arthur H, Avezum A, Bethala-Sithya M, Blumenthal M, Ceremuzynski L, De Caterina R, Diaz R, Flaker G, Frangin G, Franzosi MG, Gaudin C, Golitsyn S, Goldhaber S, Granger C, Halon D, Hermosillo A, Hunt D, Jansky P, Karatzas N, Keltai M, Lanas F, Lau CP, Le Heuzey JY, Lewis BS, Morais J, Morillo C, Oto A, Paolasso E, Peters RJ, Pfisterer M, Piegas L, Pipillis T, Proste C, Sitkei E, Swedberg K, Synhorst D, Talajic M, Tregou V, Valentin V, van Mieghem W, Weintraub W, Varigos J. Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 2006;151:1187-1193.
102. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61.
103. Disertori M, Latini R, Maggioni AP, Delise P, Pasquale GD, Franzosi MG et al. Rationale and design of the GISSI-atrial fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med 2006;7:29-38.
104. United States National Library of Medicine, National Institutes of Health. Registry of federally and privately supported clinical trials conducted in the United States and around the world. http://www.clinicaltrials.gov